Hyperpolarized Xenon ( DrugBank: Xenon )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
299嚢胞性線維症6

299. 嚢胞性線維症


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04467957
(ClinicalTrials.gov)
November 15, 202019/6/2020Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic FibrosisNon-contrast Lung Perfusion Mapping Applied for New Insights in Cystic FibrosisCystic FibrosisDrug: Initiation of CFTR Modulator;Drug: Hyperpolarized Xenon 129Children's Hospital Medical Center, CincinnatiNULLActive, not recruiting6 Years21 YearsAll26Phase 4United States
2NCT03593434
(ClinicalTrials.gov)
July 30, 201828/6/2018Airway Clearance Therapy on Hyperpolarized 129Xenon and MRIThe Effect of Airway Clearance Therapy on Hyperpolarized 129Xenon MRI Compared With Lung Clearance Index and Spirometry in Cystic FibrosisCystic FibrosisDrug: hyperpolarized Xenon gasChildren's Hospital Medical Center, CincinnatiNational Heart, Lung, and Blood Institute (NHLBI)Completed6 Years21 YearsAll20United States
3NCT03482960
(ClinicalTrials.gov)
May 29, 201823/3/2018Comparison of 129Xe MRI With 19F MRI in CF Lung DiseaseComparison of 129Xe MRI With 19F MRI in CF Lung DiseaseCystic FibrosisDrug: Hyperpolarized Xenon gas;Drug: PFPUniversity of North Carolina, Chapel HillCystic Fibrosis FoundationCompleted18 YearsN/AAll11Early Phase 1United States
4NCT02848560
(ClinicalTrials.gov)
March 201626/7/2016Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRIValidation of MRI as a Sensitive Tool to Longitudinally Monitor CF Lung Disease Progression and Response to CFTR Modulator Therapy in Young Children With CFCystic FibrosisDrug: Hyperpolarized XenonChildren's Hospital Medical Center, CincinnatiNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruiting6 Years12 YearsAll38United States
5NCT02740868
(ClinicalTrials.gov)
August 201519/8/2015Xenon-129 Lung Magnetic Resonance Imaging: Study of Healthy Volunteers and Participants With Pulmonary DiseaseDevelopment of Hyperpolarized Xenon-129 Lung Magnetic Resonance Imaging: Comparative Pilot Study of Healthy Volunteers and Participants With Pulmonary DiseaseCystic Fibrosis;AsthmaDrug: Xenon-129;Device: Magnetic Resonance Imaging;Device: Lung Clearance IndexThe Hospital for Sick ChildrenNULLRecruiting8 YearsN/AAll30Phase 2Canada
6EUCTR2019-003052-36-GB
(EUCTR)
28/02/2020Magnetic Resonance Imaging (MRI) in BronchiectasisTriple Modality Functional Magnetic Resonance Lung Imaging in Cystic Fibrosis and Non-CF Bronchiectasis - MRI in Bronchiectasis Cystic fibrosis (CF) Non-CF Bronchiectasis
MedDRA version: 21.0;Level: PT;Classification code 10006445;Term: Bronchiectasis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
MedDRA version: 20.0;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: hyperpolarized xenon-129
Product Name: hyperpolarized xenon-129
The University of NottinghamNULLNA Female: yes
Male: yes
40 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited Kingdom